<p>A new drug described as “the closest we have ever been to an HIV vaccine” could be sold for $40 a year and still make 30% profit, but is currently being sold by pharma companies for $42,250. Absolutely criminal. </p><p><a href="https://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://www.</span><span class="ellipsis">theguardian.com/global-develop</span><span class="invisible">ment/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing</span></a></p>